Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biocode MDx System, GI Pathogen Panel Get FDA 510(k) Clearance

NEW YORK (GenomeWeb) – Applied BioCode said today that it has received US Food and Drug Administration 510(k) clearance for the BioCode Gastrointestinal Pathogen Panel (GPP) with the BioCode MDx-3000 molecular system.

The BioCode GPP tests for 17 of the most common bacteria, viruses, and parasites that cause infectious diarrhea. It runs on the BioCode MDx-3000, which automates PCR amplification, hybridization/target capture, and detection, and can process up to 94 samples in about 3.5 hours or generate up to 3,196 results in an eight-hour shift, Applied BioCode said.

FDA clearance was based on the results of a clinical study of more than 1,558 prospective samples, archived positives, and contrived samples at multiple hospital-based clinical laboratories around the US.

The clearance "marks a major milestone for our company and provides yet another validation for our digital barcode magnetic bead technology," Applied BioCode President Winston Ho said in a statement. "Our BioCode MDx-3000 system will help medium to large hospitals and clinical laboratories provide automated high-volume syndromic testing to their patients at a lower overall [heathcare] cost."

Ho also noted that the GPP is the first of many syndromic panels the company expects to make available for the system.

Applied Biocode, which is based in Santa Fe Springs, California, submitted the GPP and MDx-3000 for 510(k) clearance in January. The products received CE marking in April.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.